Polymer-free Amphilimus™ eluting stent for below the knee arteries. The absence of the polymer minimizes the risk of inflammation/thrombosis, while the propriety formulation enhances drug absorption. This may contribute to maximize results in diabetic patients.
Controlled and directed drug elution as a result of the Abluminal Reservoir Technology
Optimal efficacy achieved through an homogeneous drug distribution and improved bioavailability due to the proprietary Amphilimus™ formulation, which is the combination of Sirolimus and an organic acid
Proven bio and haemo-compatibility enabled by the Bio Inducer Surface coating, which accelerates the rate of endothelization and reduces thrombogenicity
* Currently not available in US and Japan.
** The images shown within this pages are of a purely illustrative nature and not intended to depict reality.
*** Manufactured by CID S.p.A member of Alvimedica Group.